Protein Sciences Corporation Appoints New Board of Directors

Production of a Swine Flu Vaccine in a Few Weeks

MERIDEN, Conn., April 30 /PRNewswire/ -- Protein Sciences Corporation (PSC), a privately-owned biopharmaceutical company based in Meriden, CT, announced today that stockholders elected a new slate of members to the Company's Board of Directors at the 2009 Annual Meeting, held on April 28, 2009. Those Directors are:

• Daniel D. Adams, who has been CEO since July 1996, President since 1998 and a Director since May 1996. Mr. Adams also was named Chairman of the Board of Directors.
• Drs. Manon M.J. Cox, MBA, who is Chief Operating Officer.
• Anders Essen-Moller, who is Chairman and founder of Sweden-based Diamyd Medical AB, which is listed on NASDAQ OMX in Stockholm, Sweden.
• Donna R. Galluzzo, PhD., R.D., President and CEO of Homecare Management Strategies, Inc. and its division, Omni Medical Billing Plus.
• Robert B. Georgen, Chairman and CEO of Blyth, Inc., who has been a Director at PSC, since November 1995. He is also Managing Partner of The Ropart Group, a private equity firm.
• Howard E. Levine, PhD., who is Founder, President and Principal Consultant of BioProcess Technology Consultants, Inc.
• William H. Narwold, who previously served as Chairman of the Board, has been a Director since March 1992. He is a Managing Member of the law firm of Motley Rice LLC.

About PSC. PSC is a biopharmaceutical company, whose mission it is to save lives and improve health by effectively responding to our changing world with innovative vaccines and biopharmaceuticals. PSC uses recombinant DNA technology to make novel human and veterinary prophylactic and therapeutic vaccines and diagnostics. The active ingredients in all of the firm's products are recombinant proteins that are manufactured, using its patented protein expression technology, based upon baculovirus and insect cell technology.

In response to the current health emergency declared by the Department of Health and Human Services, PSC is developing a vaccine for the potential pandemic swine flu (PanBlok(R)) and expects to be manufacturing the vaccine within six weeks and to be able to produce 20,000 to 30,000 doses per week.

The Company's lead product is FluBlok(R), a seasonal recombinant trivalent influenza vaccine, consisting of influenza hemagglutin (HA) proteins. FluBlok is manufactured without the use of eggs, is highly purified and therefore does not require the use of thimerosal or antibiotics and is low in endotoxins. PSC filed a Biologics License Application for FluBlok with the FDA in April 2008 that was accepted for filing in June 2008 and received "Fast Track" designation in July, 2008. PSC anticipates that FluBlok will be approved in time for the 2009/2010 influenza season.

SOURCE Protein Sciences Corporation

RELATED LINKS
http://www.proteinsciences.com